Fosun Pharma (02696.HK): The application for the phase I clinical trial of HLX3902 injection for the treatment of metastatic castration-resistant prostate cancer and other advanced solid tumors has been approved by the National Medical Products Administration.

Zh tng cijng APP xn, f hng hn ln (02696.HK) fb gnggo, jnr, gngs zzh ynf de HLX3902 zhsh y (STEAP1xCD3xCD28 sn tyxng kngt)(HLX3902) yngy zhunyng q sh dkng xng qinli qing (mCRPC) j qt wnq sht t zhlio de 1q lnchng shyn shnqng (IND) hu guji yopn jind gunl j (NMPA) pzhn. Zh tng cijng APP News, Fuhong Hanlin (02696.HK) announced that recently, the company's self-developed HLX3902 injection (STEAP1xCD3xCD28 triple-specific antibody) for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and other advanced solid tumors has been approved for Phase 1 clinical trial application (IND) by the National Medical Products Administration (NMPA).